ZPDH:F:F-SPDR S&P U.S. Health Care Select Sector UCITS (EUR)

ETF | Others |

Last Closing

USD 40.915

Change

+0.01 (+0.01)%

Market Cap

USD 0.40B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-05 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

+0.27 (+1.02%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.43 (+0.87%)

USD 114.95B
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

USD 98.13B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

N/A

USD 91.82B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.14 (+0.93%)

USD 54.47B
VUSA:F Vanguard Funds Public Limited ..

+0.66 (+0.66%)

USD 51.63B
VUAA:F Vanguard S&P 500 UCITS Acc

+0.06 (+0.06%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

+2.55 (+1.09%)

USD 50.58B
XJSE:F Xtrackers II - Japan Governmen..

N/A

USD 40.89B
0ZC:F Zscaler Inc

+4.26 (+2.56%)

USD 37.92B

ETFs Containing ZPDH:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.79% 63% D 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.79% 63% D 65% D
Trailing 12 Months  
Capital Gain 14.16% 51% F 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.16% 51% F 59% D-
Trailing 5 Years  
Capital Gain 70.48% 87% B+ 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 70.48% 87% B+ 79% B-
Average Annual (5 Year Horizon)  
Capital Gain 12.29% 79% B- 72% C
Dividend Return 12.29% 77% C+ 65% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.94% 62% D 87% B+
Risk Adjusted Return 112.31% 99% N/A 98% N/A
Market Capitalization 0.40B 57% F 46% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike